KẾT QUẢ ĐIỀU TRỊ UNG THƯ TỤY KHÔNG PHẪU THUẬT ĐƯỢC BẰNG PHÁC ĐỒ GEMCITABINE-TS1

Abstract

Background: The Gemcitabine –TS1 combination regimen has many advantages for inoperable pancreatic cancer. In Vietnam, there is little information about the treatment results of this regimen. Purpose: Evaluation of results of treatment for unresectable pancreatic cancer with Gemcitabine - TS1 regimen. Subjects, research methods: Prospective study, cross-sectional description, longitudinal follow-up in 26 patients with inoperable pancreatic cancer which was treated with Gemcitabine - TS1 regimen at Central Hospital 108. Results: The mean age of patients at the time of diagnosis of inoperable pancreatic cancer was 65.3 years. The most common clinical symptom is abdominal pain accounting for 96.2%, jaundice as well as weight loss are 30.8%. The most common primary tumor site is the head of the pancreas, accounting for 65.4%. The most common site of metastasis is the liver, accounting for 53.8%. There were 92.3% of patients with CA19-9 elevation at the time of diagnosis and 50% of the sample patients had CA19-9 levels above 1200 UI/ml. No patient achieved a complete or partial response during the course of treatment, and the partial response and disease rates remained unchanged at 14.5% and 73.1%, respectively. Median progression-free survival and median overall survival were 5.3 months and 6.7 months respectively. The most common adverse effect was agranulocytosis and the rate of grade 3-4 agranulocytosis accounted for 19.2%. Conclusion: Gemcitabine–TS1 is a mainstay treatment for patients with unresectable pancreatic cancer.